



Check-MDR CT101
Investigate the epidemiology of suspected ESBL- and AmpC-producers with a single test
Stay on top of the epidemiology in your healthcare facility and make sure to keep antibiotic resistance at a low level. Prevention starts early.
- Discriminate directly between ESBL and non-ESBL variants of TEM and SHV
- Identify presumptive mobile AmpCs
- Obtain objective results and improve traceability with the E-Ads software
Downloads
The fact that multiple resistance genes were correctly identified whatever the complex genetic background of the tested isolates…confirms that the Check-Points array technology is a highly accurate tool for detection of coexistent bla genes
- Carbapenemases*
KPC, NDM
- CTX-M ESBLs
CTX-M-1 group, CTX-M-2 group, CTX-M-8 & -25 group, CTX-M-9 group
- TEM ESBLs vs. non-ESBL
TEM wt, TEM E104K, TEM R164S, TEM R164H, TEM G238S
- SHV ESBL vs. non-ESBL
SHV wt, SHV G238S, SHV G238A, SHV E240K
- AmpCs
CMY I/MOX, ACC, DHA, ACT/MIR, CMY II, FOX
- Controls included
DNA control, Amplification control, Hydridization control, Negative control
- Specimen
Culture
- Sample preparation
Magnetic bead- or column-based methods**
- Pre-PCR equipment
Thermocycler**, vortex mixer, mini-centrifuge
- Post-PCR equipment
Thermocycler**, vortex mixer, mini-centrifuge, thermomixer with active cooling**, Check-Points Tube Reader including E-Ads software, computer with USB drive and internet connection, barcode reader (optional)
- Throughput
3 to 72 samples/run
*KPC-2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25; NDM-1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16.
**contact your local representative for specifications
Time per step | Hands-on time per step | |
1. Culture | ||
2. DNA extraction |
||
3. Identification |
3 h | 15 min |
4. Amplification |
1.5 h |
15 min |
5. Detection through hybridization of amplified probes to specific locations on the microarray, contained in a Check-Points Array Tube |
2 h | 30 min |
6. Results are generated using the Check-Points Tube Reader to produce an image of the microarray and the E-Ads software to automatically translate this image into the presence or absence of specific beta-lactamase genes |
TEM and SHV ESBL vs. non-ESBL
Discriminate directly between ESBL and non-ESBL variants of TEM and SHV, eliminating the need for additional confirmatory sequencing. By employing a highly specific ligation reaction, wild type TEM and SHV and the exact point mutations that result in an ESBL phenotype can be accurately detected and differentiated.
Mobile AmpCs
Identify presumptive mobile AmpCs, generally associated with significantly higher beta-lactamase production than their chromosomally encoded counterparts. The finding of a particular AmpC variant in a bacterial species that naturally does not harbor it, indicates the presence of a mobile AmpC.
Objective results
Obtain objective results and improve traceability with the E-Ads software. Data is displayed immediately onscreen, summarized in a convenient format after each run and may be accessed anytime via the E-Ads software database.
Downloads
Technology
- Learn more about the technology behind our Check-MDR CT microarray assays here
Posters
Publications
- Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to 2013) and Characterization of β-Lactamase-Producing Strains. Antimicrob Agents Chemother. 2015 Jun;59(6):3509-17.
Learn more
- Bogaerts P, Hujer AM, Naas T, de Castro RR, Endimiani A, Nordmann P, Glupczynski Y, Bonomo RA. Multicenter evaluation of a new DNA microarray for rapid detection of clinically relevant bla genes from beta-lactam-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2011 Sep;55(9):4457-60.
Learn more
- Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. Prevalence of β-lactamase encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 USA hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother. 2013 Jul;57(7):3012-20.
Learn more
- Lascols C, Hackel M, Marshall SH, Hujer AM, Bouchillon S, Badal R, Haban D, Bonomo RA. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother. 2011 Sep;66(9):1992-7.
Learn more
- De Boeck H, Lunguya O, Muyembe JJ, Glupczynski Y, Jacobs J. Presence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in waste waters, Kinshasa, the Democratic Republic of the Congo. Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3085-8.
Learn more
Catalog number | Description |
10-0020 | Check-MDR CT101 kit, 72 reactions |
Accessories: | |
16-0012 | Check-Points Tube Reader incl. E-Ads Software |
Contact your local representative
For information about further equipment and supplies needed to run the assay, please refer to the “Materials required but not supplied” section of the user manual.
Other Check-Points solutions

EU: For in vitro Diagnostic Use.
US: For Research Use Only. Not for use in diagnostic procedures.